ESR1 and breast carcinoma: Due to the absence of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor (HER2) expression (Harborg et al., 2021), TNBC patients face poor prognoses and limited treatment options compared to other breast cancer subtypes.